[Federal Register Volume 89, Number 82 (Friday, April 26, 2024)]
[Notices]
[Page 32454]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2024-08986]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The invention listed below is owned by an agency of the U.S. 
Government and is available for licensing to achieve expeditious 
commercialization of results of federally-funded research and 
development. Foreign patent applications are filed on selected 
inventions to extend market coverage for companies and may also be 
available for licensing.

FOR FURTHER INFORMATION CONTACT: Licensing information may be obtained 
by communicating with the Technology Transfer and Intellectual Property 
Office, National Institute of Allergy and Infectious Diseases, 5601 
Fishers Lane, Rockville, MD 20852 by contacting Dawn Taylor-Mulneix at 
301-451-8021 or [email protected]. A signed Confidential 
Disclosure Agreement will be required to receive copies of unpublished 
information related to the invention.

SUPPLEMENTARY INFORMATION: Technology description follows:

Human Monoclonal Antibodies That Target the RH5 Complex of Blood-Stage 
Plasmodium Falciparum

Description of Technology

    249 million people were afflicted with malaria in 2022. There are 
five Plasmodium parasite species that cause malaria in humans. Of the 
five, Plasmodium falciparum causes most of the incidence of human 
disease. Most advanced malaria vaccine candidates can confer only 
partial, short-term protection in malaria-endemic areas. The 
pathogenesis of malaria is associated with blood-stage infection and 
antibodies specific to the parasite blood-stage antigens may be able to 
control parasitemia. To address this public health need, NIAID 
inventors have developed 35 human monoclonal antibodies that target the 
RH5 complex of blood-stage Plasmodium falciparum and were found to have 
potent activity in in vitro growth inhibition assays.
    This technology is available for licensing for commercial 
development in accordance with 35 U.S.C. 209 and 37 CFR part 404, as 
well as for further development and evaluation under a research 
collaboration.

Potential Commercial Applications

     Method of prophylactic and/or therapeutic treatment by 
targeting blood-stage antigens of Plasmodium.

Competitive Advantages

     Most other commercially available antibodies targeting 
against Plasmodium target circumsporozoite protein (CSP) present in the 
sporozoite stage. These novel antibodies instead target a conserved and 
essential antigen present in the blood stage: RH5.
     These monoclonal antibodies can be used alone or in 
combination with existing antibodies.

Developmental Stage

     Pre-clinical.
    Inventors: Joshua Tan, Ph.D., Lawrence Wang, Ph.D. and Andrew 
Cooper, Ph.D., all of NIAID.
    Publications: Wang, L., Cooper, A., et al. ``Natural malaria 
infection elicits rare but potent neutralizing antibodies to the blood-
stage antigen RH5.'' bioRxiv. https://www.biorxiv.org/content/10.1101/2023.10.04.560669v1, October 06, 2023.
    Intellectual Property: HHS Reference No. E-014-2023; Provisional 
Patent Application No.: 63/468,740.
    Licensing Contact: To license this technology, please contact Dawn 
Taylor-Mulneix at 301-451-8021 or [email protected], and 
reference E-014-2023.
    Collaborative Research Opportunity: The National Institute of 
Allergy and Infectious Diseases is seeking statements of capability or 
interest from parties interested in collaborative research to further 
develop, evaluate, or commercialize this technology. For collaboration 
opportunities, please contact Dawn Taylor-Mulneix at 301-451-8021 or 
[email protected].

    Dated: April 19, 2024.
Surekha Vathyam,
Deputy Director, Technology Transfer and Intellectual Property Office, 
National Institute of Allergy and Infectious Diseases.
[FR Doc. 2024-08986 Filed 4-25-24; 8:45 am]
BILLING CODE 4140-01-P